ADA: AstraZeneca's diabetes-fighter Farxiga cuts risk of fast decline in kidney function

AstraZeneca’s Farxiga is already getting a speedy FDA review as a treatment for chronic kidney disease (CKD), but it’s still piling on the positive results.

A new analysis of the company’s Declare-Timi 58 trial, presented Monday at the American Diabetes Association’s virtual annual meeting, showed the drug could reduce the proportion of patients with fast-declining estimated glomerular filtration rate (eGFR), a common measure of kidney function.